CML-MPN Associated studies
Open studies
| Short name | H-134 |
| Study title | A phase II trial in patients with myelofibrosis (primary, post-ET or post PV-MF) treated with the selective JAK2 inhibitor pacritinib before reduced-intensity conditioning allogeneic stem cell transplantation. |
| Status | Closed for inclusion |
| Participants | ZNA Stuivenberg, UZ Gasthuisberg, AZ Delta, AMC, VUMC, AZ Maastricht, Radboudumc, Erasmus MC |
| Short name | H-142 |
| Study title | Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response. |
| Status | Closed for inclusion |
| Participants | Cliniques Universitaires St. Luc, Meander MC, VUMC, Reinier de Graaf Gasthuis, Jeroen Bosch ziekenhuis, A. Schweitzer ZH, Dordwijk, Atrium MC loc Heerlen, Spaarne ziekenhuis, Radboudumc, Orbis Medisch Centr |
| Short name | Hovon-associated TARGET study |
| Study title | Individualized dosing of fludarabine during innate allo SCT; A randomized phase II study |
| Participants |
UMCU, LUMC |
Other studies, not Hovon initiated
| Short name | NAUT |
| Study title | 2nd TKI-stop After 2 Years Nilotinib Pre-treatment in Patients With First Unsuccessful Treatment Discontinuation in CML |
| Short name | DASTOP2 |
| Study title | Persistence of major molecular remission in chronic myeloid leukemia after a second stop of TKI treatment in patients who failed an initial stop attempt: A prospective multicenter study |
| Short name |
Mast cells and fibrosis in MPN (in vitro studie) |
| Participants |
Erasmus MC |
Other studies: Pharmacy-initiated study
| Short name | MANIFEST |
| Study title |
A phase 1/2 study of CPI-0610, a small molecule inhibitor of BET proteins: Phase 1 (dose escalation of CPI-0610 in patients with hematological malignancies) and Phase 2 (dose expansion of CPI-0610 with and without ruxolitinib in patients with myelofibrosis) |
| Participants | Erasmus MC, VUMC |
| Short name | CINC424BIC04 polycythemia vera: |
| Study title |
An international multi-centric observational study on the use of ruxolitinib in the treatment of patient with polycythemia vera resistant or intolerant to hydroxyurea. |
| Status |
Closed for inclusion |
| Participants | Erasmus MC, Radboud |
| Short name | FEDR-MF-002 Freedom 2 studie (Celgene/BMS) |
| Study title |
2de lijn bij ruxolitinib resistente of intolerante patienten met myelofibrose |
| Status |
Closed for inclusion |
| Participants | Radboudumc |
| Short name | ADORE (CINC424H12201) |
| Study title |
Gerandomiseerde fase I/II studie ter beoordeling van veiligheid en werkzaamheid van nieuwe ruxolitinib combinaties voor patienten met refractaire myelofibrose |
| Participants | VUMC, Erasmus MC |
Pending studies
| Short name | ACE-536-MF-002 |
| Study title |
The independence trial luspatercept versus placebo + BSC (patienten die al behandeld zijn met ruxolitinib); fase III |
| Participants | UMC Groningen |
| Short name | Transform-1 M16-191 |
| Study title |
Ruxo-navitoclax versus ruxolitinib (patienten die nooit ruxolitinib hebben gehad); fase III |
| Participants | UMC Groningen |
Closed studies
| Short name | M16-91-Transform 1 studie (Abbvie) |
| Study title | Upfront behandeling bij patienten met myelofibrose |
| Participants | Radboudumc |